Homing and Migration of Umbilical Cord Mesenchymal Stromal Cells in Clinical Applications: Molecular Mechanisms, Translational Barriers, and Therapeutic Optimization.

Umbilical cord-derived mesenchymal stromal cells (UC-MSCs) offer distinct advantages for clinical translation, including accessibility, scalability, and broad immunomodulatory capacity. However, the efficacy of systemically delivered UC-MSCs is constrained by suboptimal in vivo trafficking. Intravascular administration is limited by pulmonary first-pass sequestration, inefficient endothelial recruitment, blood-mediated inflammatory injury, and poor retention. While UC-MSCs homing is often conceptualized through a leukocyte adhesion paradigm, this model incompletely describes culture-expanded UC-MSCs, which exhibit heterogeneous expression of chemokine receptors, adhesion molecules, and selectin ligands. Furthermore, biodistribution and safety are critically determined by biophysical and hemocompatibility parameters, including cell size, deformability, cryopreservation status, and tissue factor (TF/CD142)-dependent procoagulant activity. This review synthesizes current understanding of UC-MSCs trafficking at the translational interface of biology and manufacturing. We examine canonical migratory mechanisms-chemokine signaling, integrin-mediated adhesion, extracellular matrix remodeling, and intracellular motility pathways-alongside underappreciated determinants of therapeutic performance: instant blood-mediated inflammatory reaction (IBMIR), complement-coagulation crosstalk, post-thaw functional impairment, donor variability, and route-dependent biodistribution. We also address the paradox wherein therapeutic benefit occurs despite minimal durable engraftment, implicating paracrine signaling, extracellular vesicles, and apoptosis-associated immune reprogramming as primary effectors. Finally, we evaluate strategies to enhance delivery and efficacy, including preconditioning, glycoengineering, receptor overexpression, route optimization, biomaterial-assisted retention, and migration-relevant potency assays under Good Manufacturing Practice (GMP). Advancing UC-MSCs therapy toward reproducible, mechanism-guided clinical application requires rigorous integration of hemocompatibility assessment, product characterization, and clinically informative cell tracking.